Prostatic atrophy is a benign condition characterized by shrinkage and degeneration of glandular and stromal structures of the prostate gland, and is one of the most important benign pathologies that can mimic prostate cancer on multiparametric MRI. It can be confused with adenocarcinoma by creating hypointensity on T2-weighted sequences in the peripheral zone; however, it is differentiated by its characteristic wedge-shaped or linear morphology, absence of significant diffusion restriction on DWI, and normal values on ADC map. Its prevalence increases proportionally with age, being histologically detectable in over 80% of men above 60 years. Three main morphologic patterns are defined: focal atrophy, partial atrophy, and diffuse atrophy. Proliferative inflammatory atrophy (PIA) is a special type of atrophy associated with chronic inflammation, and some studies have suggested it may be a precursor to prostate cancer. In PI-RADS v2.1, atrophy is classified as a benign finding and assessed as PI-RADS 1-2; however, atypical atrophy patterns may be interpreted as PI-RADS 3. Correct recognition of atrophy on mpMRI is critically important in reducing unnecessary biopsy rates.
Age Range
50-80
Peak Age
65
Gender
Male predominant
Prevalence
Common
Prostatic atrophy develops through shrinkage and degeneration of glandular epithelium due to chronic ischemia, inflammation, hormonal changes, or the aging process. While normal prostatic acinar epithelium consists of tall columnar cells with secretory activity, in atrophy these cells flatten, shrink, and lose secretory function. Glandular lumens narrow or close and intraluminal fluid decreases. This structural change forms the basis of T2 signal decrease on MRI: the high T2 signal of the normal peripheral zone originates from free water content in glandular lumens; in atrophy, closure of lumens and decrease in free water leads to T2 signal drop. However, atrophic tissue differs significantly from adenocarcinoma in cellular density — in atrophy cells are shrunken and loosely arranged, while in adenocarcinoma there is dense cellular packing. Therefore, there is no cellular barrier of sufficient density to restrict water molecule movement on DWI, and diffusion restriction is not observed. The wedge-shaped morphology results from atrophy following vascular supply territories (arterial distribution areas) — atrophy due to focal ischemia remains confined to a specific vascular territory creating the wedge shape.
The combination of wedge-shaped hypointensity in the peripheral zone on T2 with absence of diffusion restriction on DWI/ADC is diagnostic for atrophy. This dual pattern — morphologic (wedge) and functional (normal diffusion) — when evaluated together provides reliable differentiation from adenocarcinoma and prevents unnecessary biopsy.
On T2-weighted sequences, wedge-shaped (broad at base, tapering toward apex) or linear/band-like hypointensity is observed in the peripheral zone. This morphology follows vascular distribution territories and reflects focal ischemic atrophy. Lesion margins are smooth and sharp but do not form a round mass. May be markedly hypointense compared to normal peripheral zone signal but is differentiated from adenocarcinoma's round/oval focal hypointensity by morphology. Bilateral and multifocal involvement is common.
Report Sentence
A wedge-shaped/linear area of T2 hypointensity is identified in the [location] of the peripheral zone, consistent with prostatic atrophy when evaluated together with morphology and DWI findings.
No significant diffusion restriction is observed in the T2-hypointense atrophic area on DWI. Normal or mildly decreased values (≥1.3 × 10⁻³ mm²/s) are obtained on the ADC map. This finding is the most critical MR criterion in differential diagnosis from prostate cancer: while adenocarcinoma has marked DWI restriction (ADC <1.0 × 10⁻³ mm²/s), ADC values remain within normal limits in atrophy. On high b-value DWI (b=1400-2000), the atrophic area does not show significant signal increase.
Report Sentence
No significant diffusion restriction is detected on DWI in the T2-hypointense area (ADC: [value] × 10⁻³ mm²/s), and this finding is assessed in favor of prostatic atrophy.
On dynamic contrast-enhanced MRI (DCE), no early enhancement is observed in the atrophic area — enhancement pattern is similar to normal prostate tissue or shows less enhancement. This finding is a helpful criterion in differentiation from focal early enhancement (positive DCE) seen in adenocarcinoma. Due to decreased vascularity in atrophic tissue, contrast material accumulation remains minimal. DCE is used as an ancillary criterion in PI-RADS v2.1 for peripheral zone lesions.
Report Sentence
No early enhancement is observed in the atrophic area on DCE sequences, consistent with benign atrophy.
Mild contour retraction or local volume loss of the prostate may be observed in the atrophic area. This finding reflects shrinkage of glandular and stromal tissue and indicates that atrophy is a chronic process. In adenocarcinoma, mass effect with outward bulging is typically seen — this morphologic difference is helpful in differential diagnosis. Bilateral symmetric volume loss suggests age-related diffuse atrophy.
Report Sentence
Mild retraction of the prostate contour is observed in the atrophic area, consistent with chronic atrophic process.
May be observed as a hypoechoic area in the peripheral zone on TRUS and may be indistinguishable from the classic hypoechoic lesion of adenocarcinoma. The TRUS appearance of atrophy is nonspecific and not diagnostic alone. Wedge-shaped morphology can sometimes be detected on TRUS but is not as reliable as on MRI. Decreased vascularity in the atrophic area may be demonstrated on Doppler US — increased vascularity is expected in adenocarcinoma.
Report Sentence
A hypoechoic area is observed in the peripheral zone on TRUS, and mpMRI correlation is recommended for atrophy-cancer differentiation.
Criteria
Localized glandular atrophy in the peripheral zone. Epithelial cells flattened, lumens narrowed, basal cell layer preserved. Typical wedge-shaped T2 hypointensity.
Distinct Features
Most common type of atrophy. Typically wedge-shaped following vascular supply territory. No diffusion restriction on DWI. Low association with cancer.
Criteria
Atrophy developing in the setting of chronic inflammation. Increased proliferative activity in epithelial cells accompanied by chronic inflammatory cell infiltration. Some studies have suggested it may be a precursor of HGPIN and adenocarcinoma.
Distinct Features
May show more heterogeneous appearance than simple atrophy on mpMRI. More irregular hypointensity on T2. Inflammatory changes in surrounding tissue (diffuse T2 signal decrease, mild enhancement increase). May show mild restriction on DWI — more suspicious than simple atrophy. Biopsy may be needed.
Criteria
Widespread glandular atrophy in bilateral peripheral zones. Natural consequence of the aging process. Overall decrease in prostate volume may accompany. Diffuse hypointense appearance of peripheral zone on T2.
Distinct Features
Bilateral symmetric involvement. Peripheral zone becomes diffusely hypointense on T2 — does not form focal lesion. DWI normal. Total prostate volume may be decreased. Assessed as PI-RADS 1. Not associated with increased cancer risk.
Distinguishing Feature
Adenocarcinoma shows round/oval focal T2 hypointensity, marked DWI restriction (ADC <1.0 × 10⁻³ mm²/s), positive DCE, and mass effect. Atrophy shows wedge-shaped/linear T2 hypointensity, normal ADC, negative DCE, and volume loss/retraction. Morphology + DWI/ADC combination provides reliable differentiation.
Distinguishing Feature
In chronic prostatitis, band-like or diffuse hypointensity on T2 is seen accompanied by symptomatic clinical presentation (pain, dysuria). Atrophy is asymptomatic with predominant wedge-shaped morphology. Prostatitis may resolve after treatment (T2 signal normalizes); atrophy is irreversible. DWI may be normal in both — clinical and morphological context provides differentiation.
Distinguishing Feature
In PIN, more round/focal T2 hypointensity and gray zone ADC values (1.0-1.3 × 10⁻³ mm²/s) are seen, while in atrophy wedge-shaped morphology and normal ADC (≥1.3 × 10⁻³ mm²/s) are detected. PIN does not show volume loss while contour retraction may occur in atrophy. Both are known as cancer mimics but PIN has precursor lesion status and requires follow-up.
Distinguishing Feature
In post-biopsy hemorrhage, marked T1 hyperintensity (methemoglobin) is seen, with variable signal on T2. T1 signal is normal in atrophy. Hemorrhage is typically diffuse or linear in pattern, and correlation with biopsy history is essential. Hemorrhage resolves in 6-8 weeks; atrophy is permanent.
Urgency
routineManagement
conservativeBiopsy
Not NeededFollow-up
no-follow-upProstatic atrophy is a benign condition and when correctly identified requires no additional workup or follow-up. Its clinical significance lies in its ability to mimic prostate cancer and lead to unnecessary biopsies. The triad of wedge-shaped morphology + normal ADC + negative DCE on mpMRI reliably identifies atrophy and prevents biopsy (PI-RADS 1-2). Lesions with atypical morphology (round, focal) or mild restriction on DWI may be assessed as PI-RADS 3 and carry biopsy indication. Although proliferative inflammatory atrophy (PIA) has been considered as a potential precursor, current evidence does not recommend active surveillance or treatment for isolated PIA. PSA values may be mildly elevated in atrophy (due to inflammatory component); this can confound PSA-based cancer screening — mpMRI correlation is recommended.
Prostatic atrophy is a benign condition requiring no treatment. Recognition as a cancer mimicker is important to avoid unnecessary biopsies. DWI negativity safely differentiates atrophy from cancer. Should be reported as PI-RADS 1-2.